102 related articles for article (PubMed ID: 11454701)
21. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
Ono T; Harada M; Yamada A; Tanaka M; Takao Y; Tanaka Y; Mine T; Sakamoto K; Nakashima T; Itoh K
Clin Cancer Res; 2006 Feb; 12(4):1325-32. PubMed ID: 16489090
[TBL] [Abstract][Full Text] [Related]
23. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
[TBL] [Abstract][Full Text] [Related]
24. Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse.
Takeshita K; Yamasaki T; Akira S; Gantner F; Bacon KB
Int Immunol; 2004 May; 16(5):685-95. PubMed ID: 15096484
[TBL] [Abstract][Full Text] [Related]
25. Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L
J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979
[TBL] [Abstract][Full Text] [Related]
26. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
[TBL] [Abstract][Full Text] [Related]
27. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
28. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
[TBL] [Abstract][Full Text] [Related]
29. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
30. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging.
Guttinger M; Guidi F; Chinol M; Reali E; Veglia F; Viale G; Paganelli G; Corti A; Siccardi AG
Cancer Res; 2000 Aug; 60(15):4211-5. PubMed ID: 10945632
[TBL] [Abstract][Full Text] [Related]
32. Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth.
Kershaw MH; Darcy PK; Trapani JA; MacGregor D; Smyth MJ
Oncol Res; 1998; 10(3):133-42. PubMed ID: 9700724
[TBL] [Abstract][Full Text] [Related]
33. Identification of a tumor-associated contact-dependent activity which reversibly downregulates cytolytic function of CD8+ T cells.
Levey DL; Udono H; Heike M; Srivastava PK
Cancer Immun; 2001 Mar; 1():5. PubMed ID: 12747766
[TBL] [Abstract][Full Text] [Related]
34. [The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination].
Deligne C; Teillaud JL
Med Sci (Paris); 2013 Jan; 29(1):57-63. PubMed ID: 23351695
[TBL] [Abstract][Full Text] [Related]
35. [Role of immunologic activity of host in radiotherapy].
Tsuchiya T
Gan No Rinsho; 1983 Oct; 29(13):1499-505. PubMed ID: 6608014
[TBL] [Abstract][Full Text] [Related]
36. An antitumor cellular vaccine based on a mini-membrane IgE.
Nigro EA; Soprana E; Brini AT; Ambrosi A; Yenagi VA; Dombrowicz D; Siccardi AG; Vangelista L
J Immunol; 2012 Jan; 188(1):103-10. PubMed ID: 22124126
[TBL] [Abstract][Full Text] [Related]
37. Adriamycin-induced modulation of host defenses in tumor-bearing mice.
Maccubbin DL; Wing KR; Mace KF; Ho RL; Ehrke MJ; Mihich E
Cancer Res; 1992 Jul; 52(13):3572-6. PubMed ID: 1617626
[TBL] [Abstract][Full Text] [Related]
38. Antitumor immunity induced by laser immunotherapy and its adoptive transfer.
Chen WR; Singhal AK; Liu H; Nordquist RE
Cancer Res; 2001 Jan; 61(2):459-61. PubMed ID: 11212231
[TBL] [Abstract][Full Text] [Related]
39. [Modifying effect of IgE hyperproduction on the proliferative response of lymphocytes from intact mice and mice with transplanted tumors].
Berezhnaia NM; Koval'chuk EV; Semenova-Kobzar' RA
Eksp Onkol; 1987; 9(3):51-3. PubMed ID: 3608905
[TBL] [Abstract][Full Text] [Related]
40. Clearance of IgE from serum of normal and hybridoma-bearing mice.
Haba S; Ovary Z; Nisonoff A
J Immunol; 1985 May; 134(5):3291-7. PubMed ID: 3980994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
